Literature DB >> 24993821

5'-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors.

Keith R Laderoute1, Joy M Calaoagan2, Wan-Ru Chao2, Dominc Dinh2, Nicholas Denko3, Sarah Duellman2, Jessica Kalra4, Xiaohe Liu2, Ioanna Papandreou3, Lidia Sambucetti2, Laszlo G Boros5.   

Abstract

Rapid tumor growth can establish metabolically stressed microenvironments that activate 5'-AMP-activated protein kinase (AMPK), a ubiquitous regulator of ATP homeostasis. Previously, we investigated the importance of AMPK for the growth of experimental tumors prepared from HRAS-transformed mouse embryo fibroblasts and for primary brain tumor development in a rat model of neurocarcinogenesis. Here, we used triple-negative human breast cancer cells in which AMPK activity had been knocked down to investigate the contribution of AMPK to experimental tumor growth and core glucose metabolism. We found that AMPK supports the growth of fast-growing orthotopic tumors prepared from MDA-MB-231 and DU4475 breast cancer cells but had no effect on the proliferation or survival of these cells in culture. We used in vitro and in vivo metabolic profiling with [(13)C]glucose tracers to investigate the contribution of AMPK to core glucose metabolism in MDA-MB-231 cells, which have a Warburg metabolic phenotype; these experiments indicated that AMPK supports tumor glucose metabolism in part through positive regulation of glycolysis and the nonoxidative pentose phosphate cycle. We also found that AMPK activity in the MDA-MB-231 tumors could systemically perturb glucose homeostasis in sensitive normal tissues (liver and pancreas). Overall, our findings suggest that the contribution of AMPK to the growth of aggressive experimental tumors has a critical microenvironmental component that involves specific regulation of core glucose metabolism.
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  AMP-activated Kinase (AMPK); Glucose Metabolism; Metabolic Profiling; Triple Negative; Tumor Metabolism; Tumor Microenvironment; Warburg Effect

Mesh:

Substances:

Year:  2014        PMID: 24993821      PMCID: PMC4132788          DOI: 10.1074/jbc.M114.576371

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Fructose induces transketolase flux to promote pancreatic cancer growth.

Authors:  Haibo Liu; Danshan Huang; David L McArthur; Laszlo G Boros; Nicholas Nissen; Anthony P Heaney
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

3.  Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells.

Authors:  Min Wu; Andy Neilson; Amy L Swift; Rebecca Moran; James Tamagnine; Diane Parslow; Suzanne Armistead; Kristie Lemire; Jim Orrell; Jay Teich; Steve Chomicz; David A Ferrick
Journal:  Am J Physiol Cell Physiol       Date:  2006-09-13       Impact factor: 4.249

4.  Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction.

Authors:  David R Wise; Ralph J DeBerardinis; Anthony Mancuso; Nabil Sayed; Xiao-Yong Zhang; Harla K Pfeiffer; Ilana Nissim; Evgueni Daikhin; Marc Yudkoff; Steven B McMahon; Craig B Thompson
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-24       Impact factor: 11.205

5.  Assessment of usnic acid toxicity in rat primary hepatocytes using ¹³C isotopomer distribution analysis of lactate, glutamate and glucose.

Authors:  Bakary J Sonko; Thomas C Schmitt; Lei Guo; Qiang Shi; Laszlo G Boros; Julian E A Leakey; Richard D Beger
Journal:  Food Chem Toxicol       Date:  2011-07-23       Impact factor: 6.023

6.  [1,2-13C2]-D-glucose profiles of the serum, liver, pancreas, and DMBA-induced pancreatic tumors of rats.

Authors:  László G Boros; Megan R Lerner; Daniel L Morgan; Stephanie L Taylor; Brenda J Smith; Russell G Postier; Daniel J Brackett
Journal:  Pancreas       Date:  2005-11       Impact factor: 3.327

7.  Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells.

Authors:  J Boren; M Cascante; S Marin; B Comín-Anduix; J J Centelles; S Lim; S Bassilian; S Ahmed; W N Lee; L G Boros
Journal:  J Biol Chem       Date:  2001-08-06       Impact factor: 5.157

Review 8.  How cancer metabolism is tuned for proliferation and vulnerable to disruption.

Authors:  Almut Schulze; Adrian L Harris
Journal:  Nature       Date:  2012-11-15       Impact factor: 49.962

Review 9.  Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase.

Authors:  D G Hardie; D A Pan
Journal:  Biochem Soc Trans       Date:  2002-11       Impact factor: 5.407

10.  TKTL1 is activated by promoter hypomethylation and contributes to head and neck squamous cell carcinoma carcinogenesis through increased aerobic glycolysis and HIF1alpha stabilization.

Authors:  Wenyue Sun; Yan Liu; Chad A Glazer; Chunbo Shao; Sheetal Bhan; Semra Demokan; Ming Zhao; Michelle A Rudek; Patrick K Ha; Joseph A Califano
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

View more
  32 in total

Review 1.  Evolving Lessons on the Complex Role of AMPK in Normal Physiology and Cancer.

Authors:  Biplab Dasgupta; Rishi Raj Chhipa
Journal:  Trends Pharmacol Sci       Date:  2015-12-20       Impact factor: 14.819

2.  Differential regulation of AMP-activated protein kinase in healthy and cancer cells explains why V-ATPase inhibition selectively kills cancer cells.

Authors:  Karin Bartel; Rolf Müller; Karin von Schwarzenberg
Journal:  J Biol Chem       Date:  2019-10-11       Impact factor: 5.157

3.  Ampelopsin-induced reactive oxygen species enhance the apoptosis of colon cancer cells by activating endoplasmic reticulum stress-mediated AMPK/MAPK/XAF1 signaling.

Authors:  Ga Bin Park; Jee-Yeong Jeong; Daejin Kim
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

4.  Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.

Authors:  Tieying Dong; Xinmei Kang; Zhaoliang Liu; Shu Zhao; Wenjie Ma; Qijia Xuan; Hang Liu; Zhipeng Wang; Qingyuan Zhang
Journal:  Tumour Biol       Date:  2015-12-29

5.  Berberine Represses β-Catenin Translation Involving 4E-BPs in Hepatocellular Carcinoma Cells.

Authors:  Kanchan Vishnoi; Rong Ke; Karan S Saini; Navin Viswakarma; Rakesh Sathish Nair; Subhasis Das; Zhengjia Chen; Ajay Rana; Basabi Rana
Journal:  Mol Pharmacol       Date:  2020-10-31       Impact factor: 4.436

Review 6.  A spatiotemporal hypothesis for the regulation, role, and targeting of AMPK in prostate cancer.

Authors:  Ayesha S Khan; Daniel E Frigo
Journal:  Nat Rev Urol       Date:  2017-02-01       Impact factor: 14.432

7.  Degradation of AMPK by a cancer-specific ubiquitin ligase.

Authors:  Carlos T Pineda; Saumya Ramanathan; Klementina Fon Tacer; Jenny L Weon; Malia B Potts; Yi-Hung Ou; Michael A White; Patrick Ryan Potts
Journal:  Cell       Date:  2015-02-12       Impact factor: 41.582

Review 8.  The double-edged sword of AMPK signaling in cancer and its therapeutic implications.

Authors:  Sang-Min Jeon; Nissim Hay
Journal:  Arch Pharm Res       Date:  2015-01-10       Impact factor: 4.946

9.  Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors.

Authors:  Christopher J Matheson; Kimberly A Casalvieri; Donald S Backos; Mohammed Minhajuddin; Craig T Jordan; Philip Reigan
Journal:  Eur J Med Chem       Date:  2020-04-16       Impact factor: 6.514

Review 10.  CAF cellular glycolysis: linking cancer cells with the microenvironment.

Authors:  Amrita Roy; Soumen Bera
Journal:  Tumour Biol       Date:  2016-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.